Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

Curious about the best upcoming cars from all the major automakers available in the U.S.? You've come to the right place because we have compiled a comprehensive list of the hottest future models that ...